The median progression-free survival (mPFS) of the ensartinib group was significantly longer than that of the crizotinib group (25.8 vs 12.7 months; log-rank P < .001), meanwhile, treatment-related toxicity was well tolerated, achieving excellent efficacy in the ensartinib treatment group without the expense of safety.[12] Furthermore, in tumors with ALK mutations other than lung cancer, crizotinib is not covered by medical insurance in the Chinese mainland, although ensartinib is also self-funded, the monthly cost of crizotinib treatment is nearly 3 times that of ensartinib. This evidence concerns the gene ALK and lung carcinoma.